Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trial

Abstract

Silymarin use among patients with advanced hepatitis C-related liver disease is associated with reduced progression from fibrosis to cirrhosis, but has no impact on clinical outcomes (Clinicaltrials.gov #NCT00006164).